Brief: Epigenomics Sees 2022 Revenue Between EUR 0.3 And EUR 0.8 Mln

Epigenomics AG

11/05/2022 07:06

May 11 (Reuters) - EPIGENOMICS AG  ECXn.DE :
    * REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2022
    * REVENUES IN Q1 2022 INCREASED SLIGHTLY FROM EUR 106
THOUSAND TO
EUR 115 THOUSAND COMPARED TO PRIOR-YEAR PERIOD.
    * Q1 NET LOSS FOR PERIOD WAS EUR -2,657 THOUSAND (Q1 2021:
EUR
-1,201 THOUSAND)
    * Q1 EBITDA (BEFORE SHARE-BASED PAYMENT EXPENSES) AMOUNTED
TO EUR
-2,574 THOUSAND IN REPORTING PERIOD, COMPARED WITH EUR -985
THOUSAND IN SAME PERIOD OF PREVIOUS YEAR.
    * AS OF MARCH 31, 2022, COMPANY HAD CASH AND CASH
EQUIVALENTS OF
EUR 20,039 THOUSAND (DECEMBER 31, 2021: EUR 23,049 THOUSAND)
    * CONFIRMS ITS OUTLOOK FOR FISCAL YEAR 2022 AND CONTINUES TO
EXPECT REVENUE WITHIN RANGE OF EUR 0.3 MILLION TO EUR 0.8
MILLION.
    * FOR EBITDA (BEFORE SHARE-BASED PAYMENT EXPENSES),
EPIGENOMICS
FORECASTS FY RANGE OF EUR -15.0 MILLION TO EUR -17.0 MILLION.

Source text for Eikon:  ID:nEQ3rN3w9a 
Further company coverage:  ECXn.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))